Access Dermatology

Breaking News

• Breaking News List »

Evolution of nevi during treatment with natalizumab

A prospective follow-up was performed of a cohort of 44 multiple sclerosis (MS) patients treated with natalizumab to assess the evolution of nevi. A total of 248 nevi were examined and followed up, with a mean duration of 14 months (range 6-20 months). Seventeen lesions (6.8%) showed modifications over time and 4.8% showed substantial dermoscopic changes. Five lesions were removed; all were classified as benign. The rates of evolution of nevi in natalizumab-treated patients were similar to those reported for their spontaneous evolution in the literature. There does not appear to be any sign that natalizumab encourages the transformation of melanocytic nevi (Castela, E. et al. Arch Dermatol 2010, Advance publication).